Interferon Therapy in Follicular Lymphoma
Author Information
Author(s): Rohatiner A, Radford J, Deakin D, Earl H, Love S B, Price O, Wilson A, Lister T A
Primary Institution: ICRF Medical Oncology Unit, St. Bartholomew’s Hospital, London
Hypothesis
Does interferon improve outcomes in patients with follicular lymphoma when used as initial and maintenance therapy?
Conclusion
The addition of interferon to treatment did not improve response rates, remission duration, or survival in patients with follicular lymphoma.
Supporting Evidence
- 204 patients were randomized in the study.
- The overall response rate was 78%, with 24% achieving complete remission.
- No advantage was demonstrated for the addition of interferon.
Takeaway
This study looked at whether a medicine called interferon helps people with a type of cancer called follicular lymphoma, but it didn't make things better.
Methodology
Patients were randomized to receive either chlorambucil alone or chlorambucil with interferon, followed by maintenance therapy or expectant management.
Limitations
The study did not find any benefits from adding interferon to the treatment regimen.
Participant Demographics
Patients had newly diagnosed Stage III or Stage IV follicular lymphoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website